## User

This is the beginning of an individual meeting with Principal Investigator to discuss your research project.

Here are summaries of the previous meetings:

[begin summary 1]

To address the agenda and ensure an optimal process for developing modified nanobodies, here's the proposed plan for the iterative design process:

### 1. Order of Operations for Evaluating Mutations
In each iteration, the order of operations will be:
1. **ESM Evaluation:** Run ESM to quickly evaluate all possible single-point mutations for their potential improvement in binding affinity. This will provide an initial filter to identify promising mutations.
2. **AlphaFold-Multimer Evaluation:** For the top mutations identified by ESM, run AlphaFold-Multimer to predict the 3D structure of the nanobody-antigen complex.
3. **Rosetta Evaluation:** Use the structures predicted by AlphaFold-Multimer to run Rosetta for a more detailed assessment of binding energy.

### 2. Number of Mutations to Evaluate
In each iteration:
- **ESM:** Evaluate all possible single-point mutations (typically hundreds to thousands, as this is computationally trivial).
- **AlphaFold-Multimer:** Evaluate the top 10 mutations identified by ESM, given the time constraint (this would take approximately 5 hours).
- **Rosetta:** Evaluate these same top 10 mutations (additional 50 minutes).

### 3. Formula to Rank Nanobody Mutations
To rank the mutations, use a composite score that weighs the contributions of each tool. Here is the formula:
\[ \text{Composite Score} = w_1 \times (\text{Normalized ESM Score}) + w_2 \times (\text{Normalized AlphaFold-Multimer Score}) + w_3 \times (\text{Normalized Rosetta Score}) \]
Where \( w_1, w_2, \) and \( w_3 \) are weights that sum up to 1. A reasonable starting point could be \( w_1 = 0.2, w_2 = 0.4, w_3 = 0.4 \), given the reliability and detail provided by structural predictions and binding energies. Normalize each score to a 0 to 1 range.

### 4. Number of Top-ranked Mutations to Keep
At the end of each iteration, keep the top 3 mutations based on the composite score for further rounds of mutation. This allows exploration of the mutation space while managing computational resources efficiently.

### 5. Deciding the Number of Iterations
Continue iterations until a plateau in improvement is observed in terms of composite scores or until any of the top mutations consistently reach desirable thresholds (e.g., ESM > 9, AlphaFold-Multimer > 75, Rosetta < -35). This might typically require 5-10 iterations, depending on the initial scaffold and mutation efficacy.

### 6. Selecting the Final Set of 24 Modified Nanobodies
Once iterations are complete, follow these steps:
1. **Collect all mutations** from each iteration that were kept for the next round.
2. **Rank all these mutations** using the composite score.
3. **Select the top 24 unique modified nanobodies** based on these comprehensive rankings. Ensure diversity by including mutations from different iterations if they are closely ranked.
4. **Validate and cross-check** to ensure no redundancy in selected modifications and that they are the best candidates for experimental validation.

This process should streamline the identification of highly effective nanobody candidates for the newest SARS-CoV-2 spike protein variant, balancing speed and accuracy in computational predictions.

[end summary 1]

[begin summary 2]

To effectively utilize ESM, AlphaFold-Multimer, and Rosetta in the nanobody design process while adhering to the time constraints, the following plan addresses each agenda question:

1. **Order of Operations for Evaluating Mutations:**
   - **Step 1:** Use ESM to quickly evaluate all potential single mutations to the initial nanobody. This step will provide a rapid assessment of which mutations might positively influence binding.
   - **Step 2:** Select the top mutations based on ESM scores for further evaluation.
   - **Step 3:** Run AlphaFold-Multimer on the selected top mutations from ESM to predict the nanobody-antigen structure and evaluate the impact on binding confidence.
   - **Step 4:** Use Rosetta to score the binding energy of these structures. This step provides a detailed energetic assessment of the mutation’s impact on binding.

2. **Number of Mutations to Evaluate:**
   - In each iteration, we will initially evaluate all possible single mutations using ESM. After this, we will narrow down based on ESM scores, selecting the top 20 mutations to evaluate using AlphaFold-Multimer and Rosetta, considering the time constraints with AlphaFold-Multimer.

3. **Weighing the Scores to Rank Mutations:**
   - Given the different nature of the scoring systems, we will use a normalized scoring formula to rank the mutations:
     \[
     \text{Score} = w_1 \cdot \left( \frac{\text{ESM score} - 5}{10 - 5} \right) + w_2 \cdot \left( \frac{\text{pLDDT score} - 60}{80 - 60} \right) + w_3 \cdot \left( \frac{-\text{Rosetta score} - (-40)}{-20 - (-40)} \right)
     \]
   - Initial weights could be: \( w_1 = 0.3 \), \( w_2 = 0.3 \), \( w_3 = 0.4 \). The weights can be adjusted based on the reliability of the metrics as the process progresses.

4. **Number of Top-Ranked Mutations to Keep:**
   - From each iteration, retain the top 5 mutations based on the combined scoring to ensure diverse and strong candidates are explored in subsequent rounds.

5. **Deciding Number of Iterations:**
   - The process will iteratively introduce mutations until significant improvement in scoring metrics plateaus, or until we reach a predetermined goal, such as a 20% improvement in combined scores over the starting nanobody. Typically, this might take 3-5 iterations, which fits within the few days’ time constraint.

6. **Selecting the Final Set of 24 Modified Nanobodies:**
   - **Step 1:** Compile a list of all retained mutations across all iterations.
   - **Step 2:** Rank these mutations based on the final combined scores.
   - **Step 3:** Select the top 24 mutations from this ranked list.
   - **Step 4:** Ensure diversity among the 24 selected mutations, considering not only score but also positional diversity in the nanobody sequence to reduce the risk of convergent errors or structural incompatibilities.
   - **Step 5:** Prepare these 24 nanobody variants for experimental validation to assess their real-world binding efficiency and cross-reactivity.

By following this structured approach, we can efficiently leverage computational tools to enhance nanobody design against the newest SARS-CoV-2 variant while balancing computational resources and time constraints.

[end summary 2]

[begin summary 3]

To effectively utilize ESM, AlphaFold-Multimer, and Rosetta in our nanobody design pipeline, here is my proposed plan to address the agenda questions:

1. **Order of Operations for Evaluating Mutations:**
   - **Step 1:** Begin each iteration by using ESM to rapidly evaluate all potential single-site mutations of the nanobody. This will allow us to quickly narrow down the number of mutations based on their log-likelihood ratios.
   - **Step 2:** Select a subset of top mutations from the ESM evaluation to analyze further with AlphaFold-Multimer. Since AlphaFold-Multimer is computationally intensive, this subset should be limited to ensure the process remains efficient.
   - **Step 3:** Use AlphaFold-Multimer to predict the structures of the nanobody-antigen complexes for the selected mutations.
   - **Step 4:** Finally, employ Rosetta to calculate the binding energy scores using the structures predicted by AlphaFold-Multimer.

2. **Number of Mutations to Evaluate:**
   - **ESM:** Evaluate all possible mutations to get a broad overview.
   - **AlphaFold-Multimer and Rosetta:** Narrow this down to the top 10 mutations from ESM due to time constraints (given that the entire process should be completed in a few days).

3. **Weighing the Scores to Rank Mutations:**
   - The combined score for ranking could be calculated as:  
     \[ \text{Combined Score} = w_1 \times \text{ESM Score} + w_2 \times \text{(AlphaFold-Multimer Score)} - w_3 \times \text{(Rosetta Score)} \]
   - Where \(w_1\), \(w_2\), and \(w_3\) are weights that normalize the score ranges and balance their contributions. A reasonable starting point could be \(w_1 = 0.2\), \(w_2 = 0.4\), \(w_3 = 0.4\) based on the importance of structural and energetic considerations.

4. **Number of Top-Ranked Mutations to Keep:**
   - Keep the top 5 mutations from each iteration for further evaluation in the next iteration. This allows us to maintain diversity and explore a broader sequence space.

5. **Deciding the Number of Iterations:**
   - Run iterations until you either reach a point of diminishing returns (no significant improvement in scores) or have completed a predefined maximum number of iterations (e.g., 5 iterations). This decision can be adjusted based on observed improvements and computational constraints.

6. **Selecting the Final Set of 24 Modified Nanobodies:**
   - **Step 1:** Compile all top mutations from each iteration.
   - **Step 2:** Rank these mutations using the combined score formula across all iterations.
   - **Step 3:** Select the top 24 mutations with the best combined scores.
   - **Step 4:** Ensure diversity in the selected set to cover different regions of the spike protein and potential activity against different variants.
   - **Step 5:** Validate these 24 nanobodies experimentally to assess their binding efficiency and cross-reactivity.

This strategy optimizes the use of computational resources and aims to produce a diverse set of high-affinity nanobodies in a structured and efficient manner.

[end summary 3]

[begin summary 4]

To address the agenda questions for optimizing the development of nanobodies against the newest variant of the SARS-CoV-2 spike protein, we'll implement a strategic iterative process using ESM, AlphaFold-Multimer, and Rosetta. Here’s the detailed plan:

1. **Order of Operations in Each Iteration:**
   - **ESM Evaluation:** First, use ESM to rapidly evaluate all potential single-point mutations for their log-likelihood ratios. This will help us narrow down the number of viable mutations to evaluate with the computationally expensive AlphaFold-Multimer and Rosetta.
   - **AlphaFold-Multimer Evaluation:** Next, apply AlphaFold-Multimer to the top mutations identified by ESM to predict the 3D structure of the nanobody-antigen complex, focusing on interface pLDDT confidence scores.
   - **Rosetta Evaluation:** Finally, use Rosetta to score the binding energy of the AlphaFold-predicted structures to fine-tune the selection based on binding affinity.

2. **Number of Mutations Evaluated in Each Iteration:**
   - **ESM:** Evaluate all potential single mutations (e.g., all 19 possible amino acid substitutions for each residue in the nanobody).
   - **AlphaFold-Multimer and Rosetta:** Given the time constraints, evaluate a smaller subset (e.g., top 10 mutations) identified by ESM in each iteration.

3. **Scoring Formula for Ranking Mutations:**
   - **Composite Score = (w1 * ESM Score) + (w2 * AlphaFold-Multimer Score) + (w3 * -Rosetta Score)**
   - Weights (w1, w2, w3) should be determined based on preliminary trials or domain expertise, with higher weights for metrics reflecting more confidence in binding.
   - Normalize scores if necessary to ensure comparability.

4. **Number of Top-Ranked Mutations to Keep Each Round:**
   - Keep the top 5 mutations from each round for subsequent iterations, balancing exploration of new mutations with refinement of promising candidates.

5. **Deciding the Number of Iterations:**
   - Run a fixed number of initial iterations (e.g., 5), then evaluate progress.
   - If significant improvements are still being observed after initial iterations, consider extending or until resources are exhausted within the few days constraint.

6. **Selection of Final Set of 24 Modified Nanobodies:**
   - **Step 1:** Gather top-ranked mutations from all iterations.
   - **Step 2:** Rank all candidate nanobodies using the composite score.
   - **Step 3:** Select the top 24 unique nanobody sequences, ensuring diversity by limiting redundant or highly similar sequences.
   - **Step 4:** Perform a final review to ensure the selected nanobodies span different mutational spaces and target different epitopes or mechanisms of action.
   - **Step 5:** Prepare these 24 nanobodies for experimental validation, focusing on practical considerations like stability and manufacturability.

By following this structured approach, we ensure a balance between computational efficiency and the exploration of potential high-affinity nanobody candidates. Regular check-ins will be conducted to adapt the strategy based on real-time data and computational resource availability.

[end summary 4]

[begin summary 5]

Certainly! Here's a detailed plan to address each point on the agenda:

### 1. Order of Operations for Evaluating Mutations

**Order: ESM → AlphaFold-Multimer → Rosetta**

- **ESM**: Start by evaluating all possible point mutations of the existing nanobody using the ESM model. This is computationally efficient, allowing us to rapidly narrow down potential candidates.
  
- **AlphaFold-Multimer**: For the top candidates selected based on ESM scores, use AlphaFold-Multimer to predict the 3D structure and assess the interface pLDDT scores.
  
- **Rosetta**: Finally, use Rosetta to calculate binding energy scores based on the AlphaFold-Multimer predictions. This step fine-tunes the selection by evaluating the stability and affinity of the nanobody-antigen complex.

### 2. Number of Mutations Evaluated per Iteration

- **ESM**: Evaluate all possible single-point mutations in the nanobody sequence. Assuming a typical nanobody length of around 120 amino acids and the possibility of 19 substitutions per position (excluding the original amino acid), there would be around 2,280 mutations.

- **AlphaFold-Multimer & Rosetta**: Use a computationally feasible number, such as the top 50 mutations based on ESM scores, for the subsequent steps. This balances computational load and diversity of mutations considered.

### 3. Scoring Formula to Rank Mutations

To rank mutations, a composite score incorporating all three tools is necessary:

\[ \text{Composite Score} = w_1 \times \text{ESM Score (normalized)} + w_2 \times \text{AlphaFold-Multimer pLDDT (normalized)} - w_3 \times \text{Rosetta Binding Energy (normalized)} \]

- **Weights (w1, w2, w3)** can be initially set equal (e.g., 1/3 each) and adjusted based on empirical performance and validation.

### 4. Number of Top-Ranked Mutations to Keep

- **Top 10 Mutations**: Select the 10 highest-ranked mutations from each iteration for further exploration in the next round. This allows for sufficient diversity while maintaining focus on the most promising candidates.

### 5. Number of Iterations to Run

- Plan for **3 to 5 iterations**. The exact number can depend on the convergence of scores, diversity observed, and resource availability. Monitor convergence trends in scores and diversity of top candidates to decide when to stop.

### 6. Final Selection of 24 Modified Nanobodies

**Step-by-step Selection Process:**

1. **Compile Top Mutations**: From all iterations, compile a list of all top mutations evaluated.

2. **Re-rank with Final Scores**: Using the composite score formula, re-rank all mutations across iterations.

3. **Select 24 Diverse Nanobodies**:
   - Ensure diversity by selecting mutations that cover a range of ESM, AlphaFold-Multimer, and Rosetta scores.
   - Consider different structural or binding feature variations to maximize potential cross-reactivity with minor variants.

4. **Cross-Verify**: Re-evaluate the final 24 selections with cross-verification through additional simulation or in-silico validation if computationally feasible.

5. **Prepare for Experimental Validation**: Proceed with experimental synthesis and validation of the 24 selected nanobodies.

This plan ensures a strategic and balanced approach to nanobody design, maximizing utilization of computational resources while maintaining a focus on scientific impact.

[end summary 5]

Here is the agenda for the meeting:

Please read the summaries of multiple separate meetings about the same agenda. Based on the summaries, provide a single answer that merges the best components of each individual answer. Please use the same format as the individual answers. Additionally, please explain what components of your answer came from each individual answer and why you chose to include them in your answer.

As a reference, here is the agenda from those meetings, which must be addressed here as well:

You are working on a research project to use machine learning to develop antibodies or nanobodies for the newest variant of the SARS-CoV-2 spike protein that also, ideally, have activity against other circulating minor variants and past variants. Your team previous decided to modify existing nanobodies to improve their binding to the newest variant of the SARS-CoV-2 spike protein. Your team has built three components of a nanobody design pipeline: ESM, AlphaFold-Multimer, and Rosetta. Each of these three tools can be used to score a nanobody mutation based on how the mutation affects binding to an antigen. Your goal is to start with an existing nanobody and iteratively add mutations to it to improve its binding to the newest variant of the SARS-CoV-2 spike protein, resulting in 24 modified nanobodies with one or more mutations. Please determine how to use ESM, AlphaFold-Multimer, and Rosetta in this iterative design process. An important constraint is that ESM can evaluate all potential mutations to a nanobody in 5 minutes while AlphaFold-Multimer takes 30 minutes per mutation and Rosetta takes five minutes per mutation. The whole iterative process should take no more than a few days to complete. Note that AlphaFold-Multimer must be run before Rosetta on each mutation since Rosetta requires the nanobody-antigen structure predicted by AlphaFold-Multimer. Additionally, note that ESM log-likelihood ratios are generally in the range of 5-10 (higher is better), AlphaFold-Multimer interface pLDDT confidence scores are generally in the range of 60-80 (higher is better), and Rosetta binding energy scores are generally in the range of -20 to -40 (lower is better).

As a reference, here are the agenda questions from those meetings, which must be answered here as well:

1. In each iteration, what is the order of operations for evaluating mutations with ESM, AlphaFold-Multimer, and Rosetta?

2. In each iteration, how many mutations (give a single number) will you evaluate with ESM, AlphaFold-Multimer, and Rosetta?

3. At the end of each iteration, how will you weigh the ESM, AlphaFold-Multimer, and/or Rosetta scores (give a formula) to rank the nanobody mutations?

4. At the end of each iteration, how many of the top-ranked mutations (give a single number) will you keep for the next round?

5. How will you decide how many iterations of mutations to run?

6. After all of the iterations are complete, how exactly (step-by-step) will you select the final set of 24 modified nanobodies from across the iterations for experimental validation?



Principal Investigator, please provide your response to the agenda.

## Principal Investigator

Based on the summaries provided, here is a consolidated plan that merges the best components from each individual answer to address the agenda questions:

### 1. Order of Operations for Evaluating Mutations

**Order: ESM → AlphaFold-Multimer → Rosetta**

- **ESM**: Begin each iteration by evaluating all possible single-point mutations of the existing nanobody using ESM. This step is computationally efficient and provides a rapid assessment of potential improvements in binding.
  
- **AlphaFold-Multimer**: For the top mutations identified by ESM, use AlphaFold-Multimer to predict the 3D structure of the nanobody-antigen complex. This step focuses on evaluating the structural impact of mutations.
  
- **Rosetta**: Finally, use Rosetta to calculate the binding energy scores based on the structures predicted by AlphaFold-Multimer. This step provides a detailed energetic assessment of the mutation’s impact on binding.

**Rationale**: This order is consistently recommended across all summaries and ensures a logical progression from rapid evaluation to detailed structural and energetic analysis.

### 2. Number of Mutations to Evaluate

- **ESM**: Evaluate all possible single-point mutations (e.g., around 2,280 mutations for a typical nanobody length).
  
- **AlphaFold-Multimer and Rosetta**: Evaluate the top 10 mutations identified by ESM in each iteration due to time constraints.

**Rationale**: This approach balances computational efficiency with the need to explore a diverse set of promising mutations, as suggested in summaries 1, 3, and 4.

### 3. Formula to Rank Nanobody Mutations

\[ \text{Composite Score} = w_1 \times \left(\frac{\text{ESM Score} - 5}{10 - 5}\right) + w_2 \times \left(\frac{\text{AlphaFold-Multimer Score} - 60}{80 - 60}\right) - w_3 \times \left(\frac{\text{Rosetta Score} - (-40)}{-20 - (-40)}\right) \]

- Initial weights: \( w_1 = 0.2 \), \( w_2 = 0.4 \), \( w_3 = 0.4 \).

**Rationale**: This formula, incorporating normalization and weighting, is derived from summaries 2 and 3, providing a balanced approach to integrate different scoring systems.

### 4. Number of Top-Ranked Mutations to Keep

- Keep the top 5 mutations from each iteration for further evaluation in the next round.

**Rationale**: This number allows for maintaining diversity while focusing on the most promising candidates, as suggested in summaries 2, 3, and 4.

### 5. Deciding the Number of Iterations

- Run 5 iterations initially, then evaluate progress. Extend if significant improvements are observed or until computational resources are exhausted.

**Rationale**: This approach, recommended in summaries 1, 3, and 4, balances exploration with resource constraints.

### 6. Selecting the Final Set of 24 Modified Nanobodies

**Step-by-step Selection Process:**

1. **Compile Top Mutations**: Gather all top-ranked mutations from each iteration.
   
2. **Re-rank with Final Scores**: Use the composite score formula to re-rank all mutations across iterations.
   
3. **Select 24 Diverse Nanobodies**:
   - Ensure diversity by selecting mutations that cover a range of scores and structural variations.
   - Consider different structural or binding feature variations to maximize potential cross-reactivity with minor variants.

4. **Cross-Verify**: Re-evaluate the final 24 selections with additional in-silico validation if feasible.

5. **Prepare for Experimental Validation**: Proceed with experimental synthesis and validation of the 24 selected nanobodies.

**Rationale**: This comprehensive selection process, integrating steps from summaries 4 and 5, ensures a diverse and high-quality set of candidates for experimental validation.

This plan optimizes the use of computational resources and aims to produce a diverse set of high-affinity nanobodies in a structured and efficient manner.

